Synchronous Operable Pancreatic and Breast Cancer Without Genetic Mutation: A Literature Review and Discussion

Frontiers in Surgery

article

Adam Ofri¹  Danika Zuidersma¹  Connie I. Diakos³  Amanda Stevanovic⁵  Matthew Wong⁶  Samriti Sood⁷  Jaswinder S. Samra³  Anthony J. Gill³  Anubhav Mittal³ 

[1] Department of Surgery, Sir Charles Gairdner Hospital;St Vincent’s Clinical School, University of New South Wales;Kolling Institute of Medical Research, University of Sydney;Department of Medical Oncology, Royal North Shore Hospital;Department of Medical Oncology, Nepean Cancer Care Centre;Central Coast Cancer Centre, Gosford Hospital;Department of Breast Surgery, Royal North Shore Hospital;Upper GI Surgical Unit, Royal North Shore Hospital and North Shore Private Hospital;Australian Pancreatic Centre;Northern Clinical School, Faculty of Medicine and Health, University of Sydney;School of Medicine, Macquarie University;NSW Health Pathology, Department of Anatomical Pathology, Royal North Shore Hospital;School of Medicine, University of Notre Dame

关键词: pancreatic cancer;    breast cancer;    synchronous;    non-germline;    neoadjuvant treatment;   

DOI  :  10.3389/fsurg.2022.858349

学科分类：社会科学、人文和艺术（综合）

来源: Frontiers

【 摘 要 】

Background Synchronous cancers are rarely detected when working-up a patient for a primary cancer. Neoadjuvant management of synchronous breast and pancreatic cancers, without a germline mutation, has yet to be discussed. Two patients were diagnosed with synchronous breast and pancreatic cancers at our institution over the last decade. A literature review was performed to evaluate the current evidence stance. Results The first patient was 61-years old and diagnosed with a HER2+ breast cancer. The second patient was 77-years old and diagnosed with a Luminal B breast cancer. The inability to provide concurrent breast and pancreatic neoadjuvant therapy for the HER2+ patient, resulted in upfront surgery. The second patient was able to have both cancers treated simultaneously - neoadjuvant chemotherapy to the pancreas, and neoadjuvant endocrine therapy to the breast. Discuss There is no single neoadjuvant regimen that treats both pancreatic and breast cancer. The differences in breast cancer sub-types impacted our neoadjuvant options. Our recent experience led us to the hypothesis that breast cancer care dictates treatment, while pancreatic cancer determines survival. There is a significant paucity in the literature regarding synchronous breast and pancreatic cancer.

【 授权许可】

CC BY